Overview

Safety and Efficacy of MultiHance in Pediatric Patients

Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the safety and enhancing properties of the magnetic resonance imaging (MRI) contrast agent MultiHance in children aged 2 to 17 years having central nervous system (CNS) disorders.
Phase:
Phase 3
Details
Lead Sponsor:
Bracco Diagnostics, Inc